Fig. 1: Survival analysis in accordance with ctDNA status. | BJC Reports

Fig. 1: Survival analysis in accordance with ctDNA status.

From: Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors

Fig. 1

a Progression-free survival in accordance with ctDNA status: PFS was significantly shorter in patients with ctDNA-positive compared to those with ctDNA-negative. b Overall survival in accordance with ctDNA status: patients with ctDNA-positive exhibited a trend towards less favourable OS compared to those with ctDNA-negative.

Back to article page